3N7R

Crystal structure of the ectodomain complex of the CGRP receptor, a Class-B GPCR, reveals the site of drug antagonism

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.90 Å
  • R-Value Free: 0.267 
  • R-Value Work: 0.232 
  • R-Value Observed: 0.234 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history. 


Literature

Crystal Structure of the Ectodomain Complex of the CGRP Receptor, a Class-B GPCR, Reveals the Site of Drug Antagonism.

Ter Haar, E., Koth, C.M., Abdul-Manan, N., Swenson, L., Coll, J.T., Lippke, J.A., Lepre, C.A., Garcia-Guzman, M., Moore, J.M.

(2010) Structure 18: 1083-1093

  • DOI: 10.1016/j.str.2010.05.014
  • Primary Citation of Related Structures:  
    3N7P, 3N7R, 3N7S

  • PubMed Abstract: 

    • Dysregulation of the calcitonin gene-related peptide (CGRP), a potent vasodilator, is directly implicated in the pathogenesis of migraine. CGRP binds to and signals through the CGRP receptor (CGRP-R), a heterodimer containing the calcitonin receptor-like receptor (CLR), a class B GPCR, and RAMP1, a receptor activity-modifying protein ...

    Dysregulation of the calcitonin gene-related peptide (CGRP), a potent vasodilator, is directly implicated in the pathogenesis of migraine. CGRP binds to and signals through the CGRP receptor (CGRP-R), a heterodimer containing the calcitonin receptor-like receptor (CLR), a class B GPCR, and RAMP1, a receptor activity-modifying protein. We have solved the crystal structure of the CLR/RAMP1 N-terminal ectodomain heterodimer, revealing how RAMPs bind to and potentially modulate the activities of the CLR GPCR subfamily. We also report the structures of CLR/RAMP1 in complex with the clinical receptor antagonists olcegepant (BIBN4096BS) and telcagepant (MK0974). Both drugs act by blocking access to the peptide-binding cleft at the interface of CLR and RAMP1. These structures illustrate, for the first time, how small molecules bind to and modulate the activity of a class B GPCR, and highlight the challenges of designing potent receptor antagonists for the treatment of migraine and other class B GPCR-related diseases.

    Organizational Affiliation: 

    Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Calcitonin gene-related peptide type 1 receptor A, B115Homo sapiensMutation(s): 0 
Gene Names: CALCRL, CALRL_HUMAN, CGRPR
Find proteins for Q16602 (Homo sapiens)
Explore Q16602 
Go to UniProtKB:  Q16602
NIH Common Fund Data Resources
PHAROS:  Q16602
GTEx:  ENSG00000064989
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
Receptor activity-modifying protein 1 C, D96Homo sapiensMutation(s): 0 
Gene Names: RAMP1, RAMP1_HUMAN
Find proteins for O60894 (Homo sapiens)
Explore O60894 
Go to UniProtKB:  O60894
NIH Common Fund Data Resources
PHAROS:  O60894
GTEx:  ENSG00000132329
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
3N6
Query on 3N6
Download Ideal Coordinates CCD File 
A
N-{(1S)-5-amino-1-[(4-pyridin-4-ylpiperazin-1-yl)carbonyl]pentyl}-3,5-dibromo-Nalpha-{[4-(2-oxo-1,4-dihydroquinazolin-3 (2H)-yl)piperidin-1-yl]carbonyl}-D-tyrosinamide
C38 H47 Br2 N9 O5
ITIXDWVDFFXNEG-JHOUSYSJSA-N		 Ligand Interaction
N7R
Query on N7R
Download Ideal Coordinates CCD File 
B
N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
C26 H27 F5 N6 O3
CGDZXLJGHVKVIE-DNVCBOLYSA-N		 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
N7RIC50:  2.4000000953674316   nM  BindingDB
3N6IC50:  0.10000000149011612   nM  BindingDB
3N6IC50:  0.029999999329447746   nM  BindingDB
N7RKi:  0.800000011920929   nM  BindingDB
N7RKd :  20   nM  PDBBind
N7RIC50:  2   nM  BindingDB
N7RKd:  1.899999976158142   nM  BindingDB
3N6IC50:  0.019999999552965164   nM  BindingDB
3N6IC50:  4   nM  BindingDB
N7RIC50:  11   nM  BindingDB
N7RIC50:  2.200000047683716   nM  BindingDB
N7RKi:  0.7699999809265137   nM  BindingDB
3N6Ki:  3.4000000953674316   nM  BindingDB
3N6Ki:  0.009999999776482582   nM  BindingDB
3N6Ki:  0   nM  BindingDB
3N6EC50:  0.029999999329447746   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.90 Å
  • R-Value Free: 0.267 
  • R-Value Work: 0.232 
  • R-Value Observed: 0.234 
  • Space Group: C 2 2 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 77.94α = 90
b = 118.2β = 90
c = 133.26γ = 90
Software Package:
Software NamePurpose
DENZOdata reduction
SCALEPACKdata scaling
BUSTER-TNTrefinement
PDB_EXTRACTdata extraction
HKL-2000data collection
HKL-2000data reduction
BUSTERrefinement

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

  • Deposited Date: 2010-05-27 
  • Released Date: 2010-09-15 
    • Deposition Author(s): Ter Haar, E.

Revision History  (Full details and data files)

  • Version 1.0: 2010-09-15
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2017-11-08
    Changes: Refinement description